

Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests

- I. Tumor-type agnostic solid tumor molecular profiling panel tests (81445, 81455, 0037U, 0048U, 0250U, 0329U, 0334U, 0379U) are considered **medically necessary** when:
 - A. The member has recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, **AND**
 - B. The member is seeking further cancer treatment (e.g., therapeutic chemotherapy).
- II. Repeat testing via a tumor-type agnostic solid tumor molecular profiling panel (81445, 81455, 0037U, 0048U, 0250U, 0334U, 0379U) is considered **medically necessary** when:
 - A. The member has progression of any of the following:
 1. Advanced or metastatic non-small cell lung cancer (NSCLC), **OR**
 2. Advanced or metastatic gastric adenocarcinoma, **OR**
 3. Metastatic prostate cancer
- III. Tumor-type agnostic solid tumor molecular profiling panel tests (81445, 81455, 0037U, 0048U, 0250U, 0329U, 0334U, 0379U) are considered **investigational** for all other indications.

Note: Additional codes representing additional IHC and/or cytogenetics analyses may be billed alongside the PLA or GSP codes.

NOTES AND DEFINITIONS

1. **Advanced cancer** is cancer that is unlikely to be cured or controlled with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Treatment may be given to help shrink the tumor, slow the growth of cancer cells, or relieve symptoms.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2023. http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2023. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Occult Primary (Cancer of Unknown Primary [CUP]). Version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf